JP2015502389A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502389A5
JP2015502389A5 JP2014548078A JP2014548078A JP2015502389A5 JP 2015502389 A5 JP2015502389 A5 JP 2015502389A5 JP 2014548078 A JP2014548078 A JP 2014548078A JP 2014548078 A JP2014548078 A JP 2014548078A JP 2015502389 A5 JP2015502389 A5 JP 2015502389A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition according
stroke
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548078A
Other languages
English (en)
Japanese (ja)
Other versions
JP6127063B2 (ja
JP2015502389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076691 external-priority patent/WO2013093027A1/en
Publication of JP2015502389A publication Critical patent/JP2015502389A/ja
Publication of JP2015502389A5 publication Critical patent/JP2015502389A5/ja
Application granted granted Critical
Publication of JP6127063B2 publication Critical patent/JP6127063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548078A 2011-12-22 2012-12-21 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用 Active JP6127063B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254 2011-12-22
EP11195254.5 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (3)

Publication Number Publication Date
JP2015502389A JP2015502389A (ja) 2015-01-22
JP2015502389A5 true JP2015502389A5 (cg-RX-API-DMAC7.html) 2016-02-12
JP6127063B2 JP6127063B2 (ja) 2017-05-10

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548078A Active JP6127063B2 (ja) 2011-12-22 2012-12-21 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用

Country Status (10)

Country Link
US (1) US9452203B2 (cg-RX-API-DMAC7.html)
EP (1) EP2793935B1 (cg-RX-API-DMAC7.html)
JP (1) JP6127063B2 (cg-RX-API-DMAC7.html)
KR (1) KR102022231B1 (cg-RX-API-DMAC7.html)
CN (1) CN104080474B (cg-RX-API-DMAC7.html)
AU (1) AU2012318275B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858984C (cg-RX-API-DMAC7.html)
DK (1) DK2793935T3 (cg-RX-API-DMAC7.html)
ES (1) ES2587863T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013093027A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
LT3290046T (lt) 2013-03-15 2019-03-12 Shire Viropharma Incorporated C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
KR101508668B1 (ko) 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 c1 억제제의 용도
ES2654816T3 (es) * 2005-12-21 2018-02-15 Pharming Intellectual Property B.V. Uso del inhibidor C1 para la prevención de lesión de reperfusión de isquemia

Similar Documents

Publication Publication Date Title
JP2015502389A5 (cg-RX-API-DMAC7.html)
JP2022031772A5 (cg-RX-API-DMAC7.html)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2015518818A5 (cg-RX-API-DMAC7.html)
JP2013533858A5 (cg-RX-API-DMAC7.html)
JP2015517488A5 (cg-RX-API-DMAC7.html)
JP2016539946A5 (cg-RX-API-DMAC7.html)
JP2016516073A5 (cg-RX-API-DMAC7.html)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
JP2016514132A5 (cg-RX-API-DMAC7.html)
JP2016517421A5 (cg-RX-API-DMAC7.html)
JP2015514115A5 (cg-RX-API-DMAC7.html)
JP2016508123A5 (cg-RX-API-DMAC7.html)
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2017501154A5 (cg-RX-API-DMAC7.html)
JP2021509916A5 (cg-RX-API-DMAC7.html)
JP2018509388A5 (cg-RX-API-DMAC7.html)
JP2018521643A5 (cg-RX-API-DMAC7.html)
JP2020520916A5 (cg-RX-API-DMAC7.html)
JP2020524689A5 (cg-RX-API-DMAC7.html)
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
HK1255481A1 (zh) 用於治疗hcv的方法
JP2015524823A5 (cg-RX-API-DMAC7.html)
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法